Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of RECURSION PHARMACEUTICALS, INC. from 31 Dec 2021 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary: RECURSION PHARMACEUTICALS, INC. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
RECURSION PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $108,103,000, a 40% increase year-over-year.
RECURSION PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $644,895,000, a 39% decline year-over-year.
RECURSION PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $644,895,000, a 39% decline from 2024.
RECURSION PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $464,788,000, a 40% decline from 2023.
RECURSION PHARMACEUTICALS, INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $332,128,000, a 39% decline from 2022.
Source SEC data: View on sec.gov

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

RECURSION PHARMACEUTICALS, INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$644,895,000	$108,103,000	+$70,795,000	+40%	01 Oct 2025	31 Dec 2025	10-K	25 Feb 2026	2025	FY
Q3 2025	$715,690,000	$162,250,000	-$66,575,000	-70%	01 Jul 2025	30 Sep 2025	10-Q	05 Nov 2025	2025	Q3
Q2 2025	$649,115,000	$171,897,000	-$73,834,000	-75%	01 Apr 2025	30 Jun 2025	10-Q	05 Aug 2025	2025	Q2
Q1 2025	$575,281,000	$202,645,000	-$110,493,000	-120%	01 Jan 2025	31 Mar 2025	10-Q	05 May 2025	2025	Q1
Q4 2024	$464,788,000	$178,898,000	-$81,840,000	-84%	01 Oct 2024	31 Dec 2024	10-K	25 Feb 2026	2025	FY
Q3 2024	$382,948,000	$95,675,000	-$2,658,000	-2.9%	01 Jul 2024	30 Sep 2024	10-Q	05 Nov 2025	2025	Q3
Q2 2024	$380,290,000	$98,063,000	-$21,337,000	-28%	01 Apr 2024	30 Jun 2024	10-Q	05 Aug 2025	2025	Q2
Q1 2024	$358,953,000	$92,152,000	-$26,825,000	-41%	01 Jan 2024	31 Mar 2024	10-Q	05 May 2025	2025	Q1
Q4 2023	$332,128,000	$97,058,000			01 Oct 2023	31 Dec 2023	10-K	25 Feb 2026	2025	FY
Q3 2023		$93,017,000			01 Jul 2023	30 Sep 2023	10-Q	06 Nov 2024	2024	Q3
Q2 2023		$76,726,000			01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023		$65,327,000			01 Jan 2023	31 Mar 2023	10-Q	09 May 2024	2024	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$644,895,000	-$180,107,000	-39%	01 Jan 2025	31 Dec 2025	10-K	25 Feb 2026	2025	FY
2024	$464,788,000	-$132,660,000	-40%	01 Jan 2024	31 Dec 2024	10-K	25 Feb 2026	2025	FY
2023	$332,128,000	-$92,652,000	-39%	01 Jan 2023	31 Dec 2023	10-K	25 Feb 2026	2025	FY
2022	$239,476,000	-$52,997,000	-28%	01 Jan 2022	31 Dec 2022	10-K	28 Feb 2025	2024	FY
2021	$186,479,000			01 Jan 2021	31 Dec 2021	10-K	29 Feb 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.